Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.69 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.69 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.69 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.69 |
| ▸ | ANPEP | P15144 | 1/20 | 0.67 |
| ▸ | DPP4 | P27487 | 2/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453671 | 1.00 | DPP8 (0.69) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| SCHEMBL5816135 | 1.00 | DPP8 (0.69) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| SCHEMBL7028548 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| Hydrochloric Acid SCHEMBL7297967 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| Hydrochloric Acid SCHEMBL31717958 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| SCHEMBL7025382 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| Hydrochloric Acid SCHEMBL18770783 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| SCHEMBL7019726 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| SCHEMBL21219282 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP | |
| SCHEMBL27502334 | 0.99 | DPP8 (0.68) | DPP8DPP7SLC1A3SLC1A1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601297-A | Modified helicase and application thereof | 北京齐碳科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-114599666-A | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-113930406-A | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2022-01-14 | — | — | CN | claimed |
| US-20190127488-A1 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN | RIKEN (JP) | 2019-05-02 | — | — | US | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702156-A1 | TRNA-BASED METHODS AND RELATED COMPOSITIONS | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12521437-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | Synthorx, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-1569912-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6294674-B1 | FOR THERAPY OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, RESTENOSIS, AORTIC ANEURISM, HEART FAILURE, PERIODONTAL DISEASE, CORNEAL ULCERATION, BURNS, DECUBITAL ULCERS, CHRONIC ULCERS OR WOUNDS, CANCER METASTASIS | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | disclosed |
| EP-0680469-B1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-26 | — | — | EP | disclosed |
| US-5948925-A | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids | GENZYME CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998050418-A1 | CATIONIC AMPHIPHILES CONTAINING LINKERS DERIVED FROM NEUTRAL OR POSITIVELY CHARGED AMINO ACIDS | GENZYME CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | IL2, CCR10, IL2RA | DPP8 726/4885DPP7 1014/4885SLC1A3 3269/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | DPP8 712/4885DPP7 354/4885SLC1A3 3456/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | DPP8 466/4885DPP7 795/4885SLC1A3 3351/4885 |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | DPP8 38/4885DPP7 27/4885SLC1A3 1351/4885 |
| US-20190127488-A1 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN | NSUN3, NSUN2, LNPEP | DPP8 2708/4885DPP7 2957/4885SLC1A3 363/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | DPP8 5/4885DPP7 2/4885SLC1A3 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.